Active, not recruiting
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT02949284
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Locations
-
- Yale Cancer Center New Haven, Connecticut, United States
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States